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Purpose: To determine the influence of maximal androgen blockade (MAB) and non-MAB hormonal therapy with an luteinizing 
hormone releasing hormone (LHRH) analog on overall survival of prostate cancer patients in the Japan Study Group of Prostate Cancer 
(J-CaP) registry according to risk, as assessed using the novel J-CAPRA risk instrument. To undertake a multivariate analysis combining 
J-CAPRA risk score, type of hormonal therapy and comorbidities, in order to assess their impact on overall survival.
Methods: The J-CaP database includes men in Japan diagnosed with any stage of prostate cancer between 2001 and 2003 and 
treated with primary androgen deprivation therapy (PADT), as monotherapy or in combination. A total of 26,272 men were enrolled 
and of these 19,265 were treated with PADT. This analysis was undertaken using the latest data set (30 April, 2010) including a total of 
15,727 patients who received PADT and had follow-up data for periods ranging from 0 to 9.2 years.
Results: MAB for prostate cancer patients with intermediate- or high-risk disease has a significant benefit in terms of overall survival 
compared with LHRH analog monotherapy or surgical castration alone. Better results may be achieved in older (≥75 years) patients. 
Patient comorbidities are an important factor in determining overall survival, notably in older patients, and should be considered 
when selecting therapy.
Conclusions: Based on large-scale registry data, this report is the first to analyze the outcomes of MAB therapy in patients with 
prostate cancer at a wide range of disease stages. MAB therapy may provide significant survival benefits in intermediate- and high-risk 
patients.
Keywords: Prostate neoplasms, Maximal androgen blockade, Overall survival, Primary androgen deprivation therapy, Risk scoring
Prostate Int 2013;1(2):81-88 • http://dx.doi.org/10.12954/PI.12016
Original Article
Corresponding author: Hideyuki Akaza 
Department of Strategic Investigation on Comprehensive Cancer Network Research Center for Advanced Science and Technology, The University of Tokyo,  
4-6-1, Komaba, Meguro-ku, Tokyo 1530041, Japan 
E-mail: akazah@med.rcast.u-tokyo.ac.jp / Tel: + 81-3-5432-5341 / Fax: +81-3-5432-5343
Submitted: 28 January 2013 / Accepted after revision: 12 May 2013
INTRODUCTION
Prostate cancer is recognized as a hormone-dependent condi-
tion whereby tumour growth is stimulated by endogenous cir-
culating androgens. Therefore one of the standards of care for 
advanced, metastatic disease is primary androgen deprivation 
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CaP database 59.0% of all patients received MAB therapy and 
these regimens were most often administered to patients who 
were considered to be at high risk of disease progression [7]. 
 An exploration of the influence of the different types of 
hormonal therapy on disease outcomes concluded that MAB 
therapy was possibly superior to LHRH monotherapy in terms 
of progression-free survival (PFS) for stage II and III prostate 
cancer and overall survival for stage III and IV prostate cancer 
however the number of events was small and therefore did 
not allow any firm conclusions to be reached at that stage [7]. 
More recent follow-up data for 15,461 prostate cancer pa-
tients within the J-CaP database found that MAB therapy may 
be superior to LHRH analog monotherapy in terms of PFS for 
clinical stage II disease. In addition, disease progression ap-
pears to be inhibited in patients with clinical stage II and III 
disease receiving MAB therapy, and they were found to have a 
life expectancy similar to that of the normal population [8].
 Risk stratification of patients within the J-CaP population 
is not straightforward as there are very few published risk 
instruments that have been validated for use in the Japanese 
population and that are suitable for use with patients at all 
disease stages [9]. A novel risk instrument was recently de-
veloped and validated for patients undergoing PADT, named 
‘J-CAPRA’, details of which have been published previously 
[10]. J-CAPRA was designed and validated to be specifically 
applicable to patients receiving PADT, and more relevant than 
existing instruments to the high-risk patients that form a large 
proportion of the J-CaP database.
 This paper reports the results of an analysis of the most 
recent follow-up data from the J-CaP database to explore the 
influence of MAB and non-MAB hormonal therapy with an 
LHRH analog on overall survival of prostate cancer patients 
according to their J-CAPRA risk score. It also describes the 
results of a multivariate analysis combining J-CAPRA score, 
type of hormonal therapy, and different comorbidities, and 
their impact on overall survival.
MATERIALS AND METHODS
The J-CaP database includes men in Japan diagnosed with any 
stage of prostate cancer between 2001 and 2003 and treated 
with androgen deprivation therapy (ADT), as monotherapy or 
in combination. Three hundred eighty-four institutions con-
tributed patients, comprising approximately 50% of all men 
diagnosed in Japan during the accrual period, and nearly 95% 
of those treated with PADT. Of the patients included in the da-
tabase, 18.5% were treated in academic medical centers, and 
the remainder in the community. 
therapy (PADT) which can be achieved by either surgical cas-
tration or by medical castration using a luteinizing hormone re-
leasing hormone (LHRH) analog. Around 95% of endogenous 
testosterone is produced by the testes and while castration 
eliminates this source of the hormone, there is still a secondary 
source from the adrenal glands that is available to stimulate 
tumour growth.
 The concept of maximal androgen blockade (MAB), which 
describes the combination of an antiandrogen and either an 
LHRH analog or surgical castration, was therefore proposed 
as a therapeutic option, the aim being to eliminate both tes-
ticular and adrenal androgens simultaneously. As with every 
proposed therapeutic regimen, it is important that clinical 
evidence is generated to demonstrate its efficacy and safety 
in patients before it is recommended in treatment guidelines 
and adopted into routine clinical practice.
 In the case of MAB, since its initial proposition over 20 years 
ago there has been considerable debate regarding its relative 
benefits compared with LHRH monotherapy or castration, 
and these deliberations have been the subject of recent re-
views [1,2]. Results from randomized clinical trials (RCTs) have 
often provided equivocal results and reports of the benefits of 
MAB in terms of safety, quality of life, survival and cost effec-
tiveness have been limited [2].
 Recently the results of a Phase III, prospective RCT of MAB 
in Japanese patients with advanced prostate cancer have pro-
vided us with additional evidence of the benefits of MAB over 
LHRH analog monotherapy in terms of superior antitumor 
response, time to treatment failure, disease progression and 
overall survival, achieved without any reduction in tolerabil-
ity [3-5].
 Patient registries are also a valuable source of data on thera-
peutic efficacy and patient outcomes. In view of the extensive 
use of the different forms PADT, including MAB, for the treat-
ment of prostate cancer in Japan, in 2001 the Japan Study 
Group of Prostate Cancer (J-CaP Study Group; http://www.
j-cap.net) supported by the Japan Kidney Foundation and 
authorized by the Japanese Urological Association (JUA), com-
menced a study to gather information about hormone therapy 
administered to Japanese patients living in Japan and to ana-
lyze the outcomes of treatment. The result was the J-CaP reg-
istry, a large, multicenter, population-based database of men 
newly starting PADT for prostate cancer. 
 The rationale for development of the J-CaP database and an 
interim analysis of the registration status of the patients and 
their background variables was reported in 2003 [6] and more 
recently treatment patterns with PADT have been reported 
along with an interim analysis of prognosis [7]. Within the J-
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had follow-up data for periods ranged from 0 to 9.2 years. In 
total there were 3,399 events comprising 1,691 cancer deaths 
and 1,708 deaths due to other causes. A total of 2,549 patients 
were missing data for their Gleason score, therefore the latest 
dataset with J-CAPRA scores includes 15,727 patients.
1. Age of patients
In terms of age distribution, of the 15,727 patients who re-
ceived PADT and were included in the analysis, around 48% 
of were 75 years of age or over. Analysis of J-CAPRA risk cate-
gory (low, 0–2; intermediate, 3–7; high, 8+) by age group (≤65, 
 TNM stage (1997) was reported directly by participating 
clinicians however detailed biopsy data were not included. 
Urologists at participating institutions report follow-up find-
ings every 3 months on an ongoing basis, including informa-
tion on additional treatments, progression, and all-cause 
mortality. 
 A total of 26,272 men were enrolled in J-CaP; of these 19,265 
were treated with PADT. Additional information regarding J-
CaP has been published previously [6,7]. This current analysis 
was undertaken using the latest data set (as of 30 April, 2010) 
for 15,727 prostate cancer patients treated with PADT who 
had sufficient pathological and clinical data including follow-
up data. 
 Data for overall survival were stratified according to J-CAP-
RA risk criteria [10] and by type of hormonal therapy (MAB 
or non-MAB) received, and the patient’s age. Multivariate 
analyses were also performed to investigate the influence of 
various factors—J-CAPRA score, type of hormonal therapy, 
and different comorbidities—on overall survival. Statistical 
analysis was performed using a proportional hazards model 
(Cox regression). Prognosis analyses were performed using 
Kaplan-Meier methods. Survival analysis was tested using the 
log-rank test. Microsoft Excel was employed for depicting sur-
vival curves.
 All statistical analyses were performed using JMP ver. 8 (SAS 
Institute Inc., Cary, NC, USA).
RESULTS
Within the J-CaP database, of the 19,277 patients who initially 
received PADT after diagnosis of prostate cancer, 11,372 pa-
tients (59.0%) of all cases received MAB therapy. This latest da-
taset includes a total of 19,277 patients who received PADT and 
Fig. 1. Overall survival according to J-CAPRA risk score for all 
patients who received primary androgen deprivation therapy 
(PADT) and were included in the analysis (n=15,553, P<0.001). 
J-CAPRA score: low (0–2, blue), intermediate (3–7, red), high 
(8+, green).
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Fig. 2. Overall survival according to J-CAPRA risk score for three 
age groups of patients (≤65 [A], 66–75 [B], and >75 years of 
age [C]) who received primary androgen deprivation therapy 
(PADT) (P<0.0001). J-CAPRA score: low (0–2, blue), intermedi-
ate (3–7, red), high (8+, green).  
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66–75, >75 years of age) found a higher proportion of low-
risk patients in the older age category (48%) compared to the 
younger two age categories (45% and 31%, respectively). 
2.  Overall survival according to J-CAPRA risk score – all 
patients
Of the 15,553 patients included in this analysis who received 
PADT and had follow-up data available, 7,082 patients had a 
low J-CAPRA risk score, while 5,636 and 2,835 patients had 
intermediate and high J-CAPRA risk scores, respectively (Fig. 
1). Analysis of the overall survival of all patients who received 
PADT according to their J-CAPRA risk score found that in-
creasing J-CAPRA risk score was associated with reduced 
overall survival regardless of age (Fig. 1); P<0.0001 (overall), 
P<0.0001 (low risk vs. intermediate risk) and P<0.0001 (in-
termediate risk vs. high risk).
3.  Overall survival according to J-CAPRA risk score and 
age
Overall survival according to J-CAPRA risk score for three age 
groups of patients (≤65, 66–75, and >75 years of age) who re-
ceived PADT is shown in Fig. 2. When analyzed according to 
age category, it was found that within each age cohort increas-
ing J-CAPRA risk score was associated with reduced overall 
survival (P<0.0001). For each J-CAPRA risk group there was 
a slight tendency to reduced overall survival with increasing 
age. Overall survival estimates are shown in Table 1.
4.  Overall survival according to type of hormonal ther-
apy in younger and older patients
Overall survival according to J-CAPRA risk score for two age 
groups of patients (younger, ≤75 years; older, >75 years of 
age) who had received MAB or non-MAB hormonal therapy 
is shown in Fig. 3. In each age category the trend was similar 
with low-risk patients having a better overall survival than 
those with high-risk disease, regardless of type of hormonal 
therapy. In the younger patient subgroup (≤75 years), while 
there was no significant difference between MAB and non-
MAB therapy in terms of overall survival for patients with low 
J-CAPRA risk scores, for those with intermediate and high risk 
scores there was a significant benefit observed in favour of 
MAB therapy: intermediate risk, P=0.016; high risk, P=0.0014. 
A similar pattern was observed for the older patient subgroup: 
for intermediate- and high-risk patients MAB therapy was 
associated with significantly better overall survival than non-
MAB therapy (P=0.018 and P=0.021, respectively). 
5. Occurrence of comorbidities
The occurrence of comorbidities at the time of diagnosis of 
prostate cancer and past history of disease is shown in Fig. 4. 
It was found that hypertension occurred in around 30% of pa-
tients and diabetes in just over 10%.
6. Multivariate analysis
A multivariate analysis of overall survival in younger (≤75 
years) and older (>75 years) patients according to J-CAPRA 
score, MAB or non-MAB therapy, and three different comor-
bidities–hypertension, heart disease or stroke, diabetes, or oth-
er type of cancer–is shown in Table 2. The higher the J-CAPRA 
risk score, the greater the impact on overall survival. Low risk 
patients had significantly better overall survival than high-risk 
patients (P<0.0001) regardless of age group. MAB therapy was 
associated with significantly improved overall survival com-
pared with non-MAB therapy in both age groups (younger 
patient subgroup [hazard ratio, 0.81 vs. 1.00; P<0.001], older 
patient subgroup [hazard ratio, 0.84 vs. 1.00; P<0.023]). For 
the younger age subgroup, of the comorbidities analyzed, only 
diabetes and other type of cancer had a significant negative 
impact on overall survival (P<0.0001). However, for the older 
age subgroup, all three comorbidity variables analyzed had a 
significant negative impact on overall survival (hypertension 
or heart disease or stroke, P=0.0027; diabetes, P=0.019; other 
cancer, P<0.0001). In both age groups, MAB therapy was as-
sociated with around a 20% reduction in mortality compared 
with non-MAB therapy. 
Table 1. Overall survival according to J-CAPRA risk score and 
age of patients in the J-CaP database (n =15,727)
Age of patients (yr) Year
J-CAPRA score
0–2 3–7 8+
All data 1 0.98 0.97 0.89
3 0.93 0.85 0.6
5 0.87 0.74 0.4
7 0.81 0.64 0.27
≤65 1 0.99 0.98 0.91
3 0.97 0.88 0.63
5 0.95 0.76 0.43
7 0.92 0.66 0.31
66–75 1 0.99 0.98 0.92
3 0.95 0.89 0.62
5 0.9 0.8 0.41
7 0.85 0.71 0.25
>75 1 0.97 0.95 0.86
3 0.91 0.8 0.55
5 0.84 0.68 0.36
7 0.77 0.56 0.28
J-CaP, Japan Study Group of Prostate Cancer.
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Fig. 3. Overall survival according to J-CAPRA risk score for patients aged ≤75 years (A) and patients aged >75 years (B) who received 
maximal androgen blockade (MAB) or non-MAB hormonal therapy. PADT, primary androgen deprivation therapy.
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Fig. 4. Comorbidities and past history 
of disease at the time of diagnosis of 
prostate cancer.
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DISCUSSION
Evidence from RCTs is now accumulating to suggest the 
greater benefits of MAB compared with non-MAB hormonal 
therapy, particularly in certain subgroups of patients [3-5]. The 
most recent of these studies reported a significant survival ad-
vantage for MAB compared with LHRH analog monotherapy 
in stage C and D1 patients but not stage D2 patients, and this 
was achieved without any reduction in tolerability [4]. These 
results suggest that CAB may be more effective in prostate 
cancer patients with early-stage disease, such as C or D1. 
 This analysis of registry data from the J-CaP database sug-
gests that MAB for prostate cancer patients with intermedi-
ate- or high-risk disease has a significant benefit in terms of 
overall survival compared with LHRH analog monotherapy 
or surgical castration alone, and that better results may be 
achieved in older (≥75 years) patients.
 Results from this analysis do need to be interpreted with 
caution as the data are not randomized which does make it 
difficult to draw firm conclusions and to compare with data 
from RCTs.
 In the 1990s, while in theory MAB seemed like a useful hy-
pothesis for prostate cancer therapy, the survival advantage 
compared with surgical or medical castration alone in pub-
lished RCTs and meta-analyses was negligible and safety and 
tolerability data were lacking [11]. Results from this study and 
recent publications now suggest that the benefits of MAB in 
terms of survival may outweigh any risks, but this needs to be 
considered in the context of the individual patient’s clinical 
Table 2. Multivariate analysis of factors that impact on overall survival in patients aged ≤75 years and patients aged >75 years
Factor & level
Patients aged ≤75 yr Patients aged >75 yr
Hazard ratio P-value Hazard ratio P-value
J-CAPRA score <0.0001 <0.0001
   0–2 1.00 1.00
   3–7 2.46 2.25
   8+ 9.68 6.29
Hormone therapy 0.0010 0.0023
   Non-MAB 1.00 1.00
   MAB 0.81 0.84
Comorbidity: hypertension or heart disease or stroke 0.2000 0.0027
   No 1.00 1.00
   Yes 1.08 1.18
Comobidity: diabetes <0.0001 <0.019
   No 1.00 1.00
   Yes 1.45 1.24
Comobidity: other cancer <0.0001 <0.0001
   No 1.00 1.00
   Yes 1.90 1.40
MAB, maximal androgen blockade.
characteristics and background [3-5].
 In view of recent data on the benefits of MAB the American 
Society for Clinical Oncology recently revised its guidelines for 
the management of prostate cancer. Those published in 2004 
noted that ‘a small survival advantage’ was likely with MAB 
over castration alone, but noted that the benefits should be 
balanced against great toxicity and reduced cost-effectiveness 
[12]. The 2006 update now recommends that MAB is consid-
ered as a therapeutic option for initial hormonal management 
of androgen-sensitive, metastatic, recurrent, or progressive 
disease [13].
 The results of this current analysis also demonstrate that 
patient comorbidities are an important factor in determining 
overall survival, most notably in older patients and should 
be a key consideration when selecting appropriate therapy. 
Several recent studies have reported a relationship in patients 
with prostate cancer between ADT with LHRH therapy (with 
or without an antiandrogen) and an increased risk of cardio-
vascular disease; some studies, but not all, have also reported 
an increase in the risk of cardiovascular death [14-18]. This 
has focused discussion on the metabolic effects of ADT and 
the possible association with increased cardiovascular risk. 
As a result, advice for the prescribing clinician has been is-
sued jointly by the American Heart Association, American 
Cancer Society, and American Urological Association which 
recommends monitoring blood pressure and lipid and blood 
glucose levels before the start of ADT, within 3–6 months after 
the start of therapy, and then on an annual basis if treatment 
is continued [19]. These recommendations apply to all forms 
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of ADT and there is no specific advice at the present time re-
lating to MAB therapy.
 The study undertaken by Akaza et al. [20] demonstrated no 
difference in overall survival between patients with localized 
prostate cancer treated with PADT and men of the same age 
in the general population, suggesting that there is no signifi-
cant increase in mortality in men treated with PADT. These 
findings are supported by recent analyses showing that the 
incidence of cardiovascular events in patients registered in J-
CaP database from 2001–2003 and treated with PADT was no 
greater than that expected in general Japanese population [8]. 
In addition, data from a large national prostate cancer patient 
registry in the USA, the Cancer of the Prostate Strategic Uro-
logic Research Endeavor database, also demonstrated no in-
creased risk of cardiovascular mortality with use of ADT [21].
 Due to the particularly hormone-sensitive nature of the 
prostate cancer the search is continuing for new, more ef-
fective types of hormonal therapy and a range of different 
compounds is currently under investigation that act at various 
points along the pathway to androgen generation and target 
all possible sources: testicular, adrenal, those produced in 
the prostate gland itself or by other peripheral tissues. These 
include agents that exert their effects at the androgen receptor 
and those that inhibit hormone synthesis [22]. Such develop-
ments in therapy will undoubtedly be of particular importance 
for patients with metastatic prostate cancer which presents 
major therapeutic challenge once resistance to hormonal 
therapy develops. As clinicians are aware, when treating pros-
tate cancer patients with PADT it is important to select an 
appropriate therapy for the individual patient that provides 
optimum efficacy while also minimizing adverse events. It is 
hoped that new, more selective antiandrogenic agents may 
also potentially reduce the incidence of the adverse events that 
are commonly associated with currently available hormonal 
therapy and mean that PADT could be used to treat a wider 
range of prostate cancer patients.
 The overall results of this analysis of prostate cancer pa-
tients within the J-CaP database suggest that PADT in the form 
of a MAB regimen may provide significant survival benefits in 
some patients but that further data from RCTs and large regis-
tries are required to support the current thinking and to help 
identify patients who are most suited to this form of therapy.
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